Citigroup Inc Poseida Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 49,986 shares of PSTX stock, worth $474,867. This represents 0.0% of its overall portfolio holdings.

Number of Shares

49,986

Previous 15,382 224.96%

Holding current value

$474,867

Previous $44,000 222.73%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.7 - $4.04 $93,430 - $139,800	34,604 Added 224.96%	49,986 $142,000
Q2 2024 Aug 12, 2024	BUY	$2.0 - $3.46 $5,062 - $8,757	2,531 Added 19.69%	15,382 $44,000
Q1 2024 May 10, 2024	BUY	$2.76 - $4.13 $8,343 - $12,484	3,023 Added 30.76%	12,851 $40,000
Q4 2023 Feb 09, 2024	BUY	$1.83 - $3.51 $15,928 - $30,551	8,704 Added 774.38%	9,828 $33,000
Q3 2023 Nov 09, 2023	SELL	$1.62 - $2.79 $33,349 - $57,434	-20,586 Reduced 94.82%	1,124 $2,000
Q2 2023 Aug 10, 2023	SELL	$1.66 - $3.4 $171,526 - $351,318	-103,329 Reduced 82.64%	21,710 $38,000
Q1 2023 May 11, 2023	SELL	$3.08 - $8.73 $118,998 - $337,292	-38,636 Reduced 23.61%	125,039 $385,000
Q4 2022 Feb 09, 2023	BUY	$3.33 - $6.38 $535,560 - $1.03 Million	160,829 Added 5651.05%	163,675 $867,000
Q3 2022 Nov 10, 2022	BUY	$2.43 - $4.51 $3,508 - $6,512	1,444 Added 103.0%	2,846 $10,000
Q2 2022 Aug 10, 2022	SELL	$1.87 - $5.0 $4,403 - $11,775	-2,355 Reduced 62.68%	1,402 $4,000
Q1 2022 May 12, 2022	SELL	$3.22 - $7.04 $17,075 - $37,333	-5,303 Reduced 58.53%	3,757 $17,000
Q4 2021 Feb 10, 2022	BUY	$6.23 - $7.6 $15,045 - $18,354	2,415 Added 36.34%	9,060 $62,000
Q3 2021 Nov 10, 2021	BUY	$7.09 - $10.71 $47,113 - $71,167	6,645 New	6,645 $48,000

Others Institutions Holding PSTX

# of Institutions

Shares Held

38.5M

Call Options Held

377K

Put Options Held

22.2K

View Full List

About Poseida Therapeutics, Inc.

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $815M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

More about PSTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account